Pilot study suggests DNA methylation of the glucocorticoid receptor gene (NR3C1) is associated with MDMA-assisted therapy treatment response for severe PTSD
BackgroundPrevious research has demonstrated that epigenetic changes in specific hypothalamic-pituitary-adrenal (HPA) genes may predict successful psychotherapy in post-traumatic stress disorder (PTSD). A recent Phase 3 clinical trial reported high efficacy of 3,4-methylenedioxymethamphetamine (MDMA...
Main Authors: | Candace R. Lewis, Joseph Tafur, Sophie Spencer, Joseph M. Green, Charlotte Harrison, Benjamin Kelmendi, David M. Rabin, Rachel Yehuda, Berra Yazar-Klosinski, Baruch Rael Cahn |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-02-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2023.959590/full |
Similar Items
-
The use of 3,4-Methylenedioxymethamphetamine (MDMA) in the treatment of Post-Traumatic Stress Disorder (PTSD) - review
by: Karol Womperski, et al.
Published: (2023-08-01) -
MDMA-assisted therapy is associated with a reduction in chronic pain among people with post-traumatic stress disorder
by: Devon Christie, et al.
Published: (2022-11-01) -
MDMA-assisted psychotherapy for people diagnosed with treatment-resistant PTSD: what it is and what it isn’t
by: Louise Morgan
Published: (2020-05-01) -
MDMA (éxtasis): usos y potencialidades terapéuticas
by: José Carlos Bouso S., et al.
Published: (2003-12-01) -
A comparison of mdma-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis
by: B. Illingworth, et al.
Published: (2021-04-01)